These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22133734)

  • 1. [Management of chemotherapy in hemodialysis patients].
    Janus N; Launay-Vacher V; Deray G; Thyss A; Thariat J
    Bull Cancer; 2012 Mar; 99(3):371-80. PubMed ID: 22133734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drugs in End-Stage Kidney Disease Patients.
    Janus N; Launay-Vacher V
    Semin Dial; 2015; 28(4):413-6. PubMed ID: 25864698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of targeted therapies in hemodialysis patients].
    Janus N; Launay-Vacher V; Deray G; Islam MS; Thyss A; Thariat J
    Bull Cancer; 2012 Mar; 99(3):381-8. PubMed ID: 22133789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.
    Janus N; Thariat J; Boulanger H; Deray G; Launay-Vacher V
    Ann Oncol; 2010 Jul; 21(7):1395-1403. PubMed ID: 20118214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticancer drugs management in renal insufficiency patients].
    Zimmer-Rapuch S; Lheureux S; Brocard F; Janus N; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 Mar; 99(3):323-31. PubMed ID: 22123599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.
    Tomita M; Aoki Y; Tanaka K
    Clin Pharmacokinet; 2004; 43(8):515-27. PubMed ID: 15170366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FHD: an index to evaluate drug elimination by hemodialysis.
    Launay-Vacher V; Izzedine H; Baumelou A; Deray G
    Am J Nephrol; 2005; 25(4):342-51. PubMed ID: 15980618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study.
    Janus N; Launay-Vacher V; Thyss A; Boulanger H; Moranne O; Islam MS; Durande JP; Ducret M; Juillard L; Soltani Z; Motte G; Rottembourg J; Deray G; Thariat J
    Ann Oncol; 2013 Feb; 24(2):501-507. PubMed ID: 23038759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.
    Janus N; Launay-Vacher V
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):617-623. PubMed ID: 28537215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients.
    Onuigbo MA; Nye D; Iloanya PC
    Adv Perit Dial; 2009; 25():89-91. PubMed ID: 19886325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis.
    Jillella AP; Dainer PM; Kallab AM; Ustun C
    Am J Hematol; 2002 Nov; 71(3):219-22. PubMed ID: 12410580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
    Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure].
    Olszewska M
    Ann Acad Med Stetin; 2004; 50(1):41-52. PubMed ID: 16871743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.